Houdini Bio emerges from stealth with €1.7M for DNA silencing

What happened?

British startup Houdini Bio has emerged from stealth mode, announcing a pre-seed funding round of approximately €1.7 million (£1.5 million). The round was led by SCVC (the investment arm of Science Creates), with participation from Deep Science Ventures and University of Cambridge (Cambridge Enterprise VC). The company will use the funds to validate its DNA sequence design platform, which aims to overcome DNA silencing mediated by the HUSH complex, one of the main cellular mechanisms that reject gene therapies. According to the startup, the funding allowed it to validate its technology in a third of the expected time, reaching projected technical milestones in just a few months.

Why is it important?

Gene therapies have proven capable of curing previously untreatable diseases, such as spinal muscular atrophy or certain hemoglobinopathies, but their long-term effectiveness is limited because cells tend to silence therapeutic DNA. This phenomenon, known as transgene silencing, is largely mediated by the HUSH complex, a cellular mechanism that recognizes and represses exogenous DNA sequences rich in repeats. As a result, patients require higher and repeated doses, increasing costs (a gene therapy can cost between $500,000 and $2 million per patient) and safety risks, such as adverse immune responses. Houdini Bio proposes a DNA engineering approach based on molecular rules to avoid that silencing, rather than traditional trial-and-error methods. According to its CEO, Jonathan Cohen-Gold, the platform enables repeatable, engineering-based design, providing the 'missing link' between gene therapies and patients. The investment aligns with a broader trend in 2026 where capital flows toward biotech infrastructure companies that remove bottlenecks in drug development. Recent examples include Ternary Therapeutics (AI-driven molecule design, which raised €4.1 million in March), Tozaro (optimization of cell and gene therapy manufacturing, with €6.9 million in February), and Primogene (enzymatic biomanufacturing, €4.1 million in April). These rounds reflect a shift in focus: investors are no longer betting solely on individual therapeutic assets, but on platforms that solve fundamental value chain problems.

Consequences and context

Houdini Bio operates in a very early segment of the value chain, focusing on DNA engineering to avoid cellular silencing mechanisms, rather than addressing specific disease indications or downstream manufacturing. This positions it as an enabling platform that could benefit multiple therapies, from in vivo gene therapies to cell therapies like CAR-T. The HUSH complex, discovered in 2015 by Didier Trono's lab at EPFL, is a particularly relevant target: it is known to silence viral DNA and transgenes in human cells, and its inhibition could improve the persistence of therapeutic gene expression. Geographically, the UK ecosystem (London and Cambridge) shows a significant concentration of funding rounds in AI-enabled biotech infrastructure, with amounts exceeding €4 million. Cambridge, in particular, hosts a world-class biotech cluster, with institutions like the Wellcome Sanger Institute and the MRC Laboratory of Molecular Biology, providing a fertile environment for startups like Houdini Bio. For readers, the news underscores that the next frontier in gene therapies is not just discovering new targets, but solving fundamental problems of delivery and persistence of therapeutic DNA. Companies like Houdini Bio could be key to making these therapies safer, more effective, and more affordable, potentially reducing costs by enabling lower and less frequent doses.

"Our platform introduces a vital shift, moving from trial-and-error screening to repeatable, engineering-based DNA design," says Jonathan Cohen-Gold, CEO of Houdini Bio.

Furthermore, Houdini Bio's approach could have implications beyond gene therapies, such as in CRISPR gene editing, where the persistence of correction also depends on avoiding silencing. If the platform succeeds, it could become a standard for therapeutic sequence design, similar to how AI-based protein design tools are transforming drug discovery.

What readers should know

• The €1.7M pre-seed funding allowed Houdini Bio to validate its technology in a third of the expected time, reaching technical milestones in months instead of a year.
• The HUSH complex is a cellular mechanism that silences exogenous DNA rich in repeats, limiting the long-term efficacy of gene therapies. It was identified in 2015 and has since been studied as a potential target to improve transgene expression.
• The startup was founded in 2025 by Jonathan Cohen-Gold and his team, and belongs to the 'DeepTech infrastructure' category attracting investment in 2026, according to EU-Startups analysis.
• The round reflects investor interest in platforms that solve biological bottlenecks rather than individual therapeutic assets, a trend observed across Europe.
• The Cambridge (UK) ecosystem is a key biotech hub, with a strong presence of venture capital and scientific talent, favoring the emergence of startups like Houdini Bio.

In summary, Houdini Bio represents a bet on technological infrastructure that could unlock the true potential of gene therapies, addressing one of the biggest obstacles: the persistence of therapeutic DNA in cells. While the company is in a very early stage, its molecular rule-based approach and rapid technical validation make it a startup to watch in the European biotech landscape.